Clinical Trial Update: Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a PD-1 inhibitor with Capecitabine and Oxaliplatin (CapOx) as first-line therapy for dMMR esophagogastric cancer; recruitment …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• PD-1 inhibitor

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Status: RECRUITING